biote Corp.

As of August 7, 2025, biote Corp. is in a bearish trend, indicated by negative signals from MACD, moving averages, and Bollinger Bands, with a year-to-date return of -45.47% compared to the S&P 500's 12.22%.

As of June 22, 2022, Biote Corp. is considered a risky investment but appears undervalued with a low P/E ratio of 5.23, suggesting potential growth despite recent struggles and a year-to-date return of -35.11%.

As of May 8, 2024, Biote Corp. shows a moderate bullish trend with mixed signals: weekly indicators are mildly bullish while monthly indicators remain bearish, suggesting short-term strength but potential longer-term weakness.

biote Corp. is a micro-cap company in the hospital industry, reporting net sales of $49 million and a net profit of $16 million as of March 2025. Key financial metrics include a P/E ratio of 5.00 and a market cap of $156.74 million.

As of Jun 18, biote Corp. has a market capitalization of 156.74 million, with net sales of 199.37 million and a net profit of 21.51 million over the latest four quarters. The balance sheet shows shareholder's funds of -105.93 million and total assets of 122.37 million.